File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Allogeneic bone marrow transplantasion for severe aplastic anemia: The Hong Kong scenario

TitleAllogeneic bone marrow transplantasion for severe aplastic anemia: The Hong Kong scenario
Authors
Issue Date1998
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1998, v. 16 n. 2, p. 41-46 How to Cite?
AbstractSevere aplastic anemia (SAA) is a disease associated with high mortality. For young patients with HLA identical siblings, allogeneic bone marrow transplantation (BMT) offers the best chance of cure. Favourable results have also been reported using immunosuppressive therapy (IST). Transplantation is usually favoured for patients below 45 years of age. We report our experience of 11 allogeneic and one syngeneic BMT for adult Chinese patients with SAA, over a 4-year period from 1991 to 1995. Ten of the 12 (83 per cent) patients had received and failed prior IST including anti- thymocyte globulin (ATG) before being referred for BMT. Neutrophil and platelet engraftment was successful in 11 of them (92 per cent) and nine were completely transfusion independent after transplantation. Their overall 3- year survival was 67 per cent. The compromised overall result was due to a number of cases transplanted after a long time delay. No patient transplanted beyond 3 years from the initial time of diagnosis of SAA achieved long-term marrow engraftment, and they all eventually succumbed. On univariate analysis, a longer time delay and hence a larger amount of blood products exposure, were highly significantly statistically associated with inferior marrow engraftment and patient survival. Other factors including age, iron status, infused cell dose and the conditioning protocol were not found to significantly affect engraftment and survival. Graft versus host disease was clinically mild or absent in most patients. This may be related to ethnicity or previous ATG exposure. In conclusion, early allogeneic BMT was a safe and effective treatment in our small series of patients with SAA failing IST.
Persistent Identifierhttp://hdl.handle.net/10722/162259
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorKwong, YLen_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorChim, CSen_US
dc.contributor.authorLee, CKen_US
dc.contributor.authorChiu, EKWen_US
dc.contributor.authorLiang, Ren_US
dc.date.accessioned2012-09-05T05:18:27Z-
dc.date.available2012-09-05T05:18:27Z-
dc.date.issued1998en_US
dc.identifier.citationHematological Oncology, 1998, v. 16 n. 2, p. 41-46en_US
dc.identifier.issn0278-0232en_US
dc.identifier.urihttp://hdl.handle.net/10722/162259-
dc.description.abstractSevere aplastic anemia (SAA) is a disease associated with high mortality. For young patients with HLA identical siblings, allogeneic bone marrow transplantation (BMT) offers the best chance of cure. Favourable results have also been reported using immunosuppressive therapy (IST). Transplantation is usually favoured for patients below 45 years of age. We report our experience of 11 allogeneic and one syngeneic BMT for adult Chinese patients with SAA, over a 4-year period from 1991 to 1995. Ten of the 12 (83 per cent) patients had received and failed prior IST including anti- thymocyte globulin (ATG) before being referred for BMT. Neutrophil and platelet engraftment was successful in 11 of them (92 per cent) and nine were completely transfusion independent after transplantation. Their overall 3- year survival was 67 per cent. The compromised overall result was due to a number of cases transplanted after a long time delay. No patient transplanted beyond 3 years from the initial time of diagnosis of SAA achieved long-term marrow engraftment, and they all eventually succumbed. On univariate analysis, a longer time delay and hence a larger amount of blood products exposure, were highly significantly statistically associated with inferior marrow engraftment and patient survival. Other factors including age, iron status, infused cell dose and the conditioning protocol were not found to significantly affect engraftment and survival. Graft versus host disease was clinically mild or absent in most patients. This may be related to ethnicity or previous ATG exposure. In conclusion, early allogeneic BMT was a safe and effective treatment in our small series of patients with SAA failing IST.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_US
dc.relation.ispartofHematological Oncologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAnemia, Aplastic - Therapyen_US
dc.subject.meshBone Marrow Transplantationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunosuppressive Agents - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshRetreatmenten_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshTransplantation, Homologousen_US
dc.titleAllogeneic bone marrow transplantasion for severe aplastic anemia: The Hong Kong scenarioen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.emailChim, CS:jcschim@hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.identifier.authorityChim, CS=rp00408en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/(SICI)1099-1069(199806)16:2<41::AID-HON621>3.0.CO;2-Oen_US
dc.identifier.pmid10065111-
dc.identifier.scopuseid_2-s2.0-0032419350en_US
dc.identifier.hkuros49649-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032419350&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume16en_US
dc.identifier.issue2en_US
dc.identifier.spage41en_US
dc.identifier.epage46en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridChim, CS=7004597253en_US
dc.identifier.scopusauthoridLee, CK=7410162028en_US
dc.identifier.scopusauthoridChiu, EKW=24827833600en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats